Yes, for trading in and out. For long term, I would say it's a HOLD or a BUY due to potential successful wider application of Cabo. Do not forget that Cabo is already approved for an application and that it's being tried for other oncology applications and some are going to succeed. But, for that, you may have to wait for at least a couple of more quarters. Besides that the company has many collaborations with major pharmas. This company is much more on the solid ground than Geron which the two bozos have reduced to a one-product company!!